EU-MEDICAL_DEVICES_REGULATION-ANX_I_SEC_10
EU-MEDICAL_DEVICES_REGULATION-ANX_I_SEC_10
Medical Devices Regulation - Hazardous Substances
EU. Hazardous Substances for Purposes of Medical Devices Regulation 2017/745/EU, 5 May 2017, as amended by Regulation 2020/561/EU, 24 April 2020
This list contains hazardous substances for purposes of the Medical Devices Regulation (MDR), based on the legislation's Annex I general safety and performance requirements, including for chemical, physical and biological properties. Specifically, the non-exhaustive database is derived from: Table 3 of Annex VI to CLP, REACH Candidate List of SVHCs, and Directive 2000/54/EC's Annex III (Biological Agents list).
Last updated 10 mei 2024. Database contains 4917 unique substances/entries.
Filter the list
|
278-636-5
|
77182-82-2
|
Repr. 1B; Acute Tox. 4; STOT RE 2 |
Details | |||
|
EW 400; GLUCOPROTAMIN
|
403-950-8
|
164907-72-6
|
Acute Tox. 2; Acute Tox. 4; Skin Corr. 1B |
Details | ||
|
203-856-5
|
111-30-8
|
Acute Tox. 2; Acute Tox. 3; STOT SE 3; Skin Corr. 1B; Resp. Sens. 1; Skin Sens. 1A |
RSP Respiratory sensitising properties (Article 57(f)) - human health) |
Details | ||
|
200-240-8
|
55-63-0
|
Expl. 1.1; Acute Tox. 2; Acute Tox. 1; STOT RE 2 |
Details | |||
|
200-240-8
|
55-63-0
|
Unst. Expl.; Acute Tox. 2; Acute Tox. 1; STOT RE 2 |
Details | |||
|
203-474-9
|
107-22-2
|
Muta. 2; Acute Tox. 4; Eye Irrit. 2; Skin Irrit. 2; Skin Sens. 1 |
Details | |||
|
206-058-5
|
298-12-4
|
Eye Dam. 1; Skin Sens. 1B |
Details | |||
|
213-997-4
|
1071-83-6
|
Eye Dam. 1 |
Details | |||
|
617-243-9
|
81591-81-3
|
Acute Tox. 4 |
Details | |||
|
219-468-4
|
2439-99-8
|
Eye Dam. 1 |
Details | |||
|
201-964-7
|
90-05-1
|
Acute Tox. 4; Eye Irrit. 2; Skin Irrit. 2 |
Details | |||
|
-
|
-
|
V Viruses: Member States are to ensure that all viruses which have already been isolated in humains and which have not been assessed and allocated in this Annex are classified in group 2 as a minimum, except where Member States have proof that they are unlikely to cause disease in humans. |
Details | |||
|
GUANIDINIUMBENZOAT
|
429-820-0
|
26739-54-8
|
Acute Tox. 4 |
Details | ||
|
200-002-3
|
50-01-1
|
Acute Tox. 4; Eye Irrit. 2; Skin Irrit. 2 |
Details | |||
|
620-427-1
|
108173-90-6
|
Acute Tox. 2; Acute Tox. 4; STOT SE 3; Skin Irrit. 2; Eye Dam. 1 |
Details | |||
|
-
|
-
|
B Bacteria and similar species |
Details | |||
|
-
|
-
|
B Bacteria and similar species |
Details | |||
|
-
|
-
|
B Bacteria and similar species |
Details | |||
|
TILCOM HTB
|
411-740-2
|
22411-22-9
|
Eye Dam. 1; Skin Sens. 1 |
Details | ||
|
600-130-3
|
100784-20-1
|
Repr. 1B |
Details | |||
|
HALOXYFOP ETHOXYETHYL EST
|
402-560-5
|
87237-48-7
|
Acute Tox. 4 |
Details | ||
|
-
|
-
|
V Viruses: Member States are to ensure that all viruses which have already been isolated in humains and which have not been assessed and allocated in this Annex are classified in group 2 as a minimum, except where Member States have proof that they are unlikely to cause disease in humans. |
Details | |||
|
-
|
-
|
V Viruses: Member States are to ensure that all viruses which have already been isolated in humains and which have not been assessed and allocated in this Annex are classified in group 2 as a minimum, except where Member States have proof that they are unlikely to cause disease in humans. |
Details | |||
|
-
|
-
|
V Viruses: Member States are to ensure that all viruses which have already been isolated in humains and which have not been assessed and allocated in this Annex are classified in group 2 as a minimum, except where Member States have proof that they are unlikely to cause disease in humans. |
Details | |||
|
-
|
12035-71-1
|
Carc. 1A; Muta. 2; Acute Tox. 3; STOT RE 1; Skin Sens. 1 |
Details | |||
|
-
|
-
|
B Bacteria and similar species |
Details | |||
|
218-165-4
|
2058-94-8
|
VPVB very Persistent and very Bioaccumulative (article 57e) |
Details | |||
|
-
|
-
|
V Viruses: Member States are to ensure that all viruses which have already been isolated in humains and which have not been assessed and allocated in this Annex are classified in group 2 as a minimum, except where Member States have proof that they are unlikely to cause disease in humans. |
Details | |||
|
-
|
-
|
V Viruses: Member States are to ensure that all viruses which have already been isolated in humains and which have not been assessed and allocated in this Annex are classified in group 2 as a minimum, except where Member States have proof that they are unlikely to cause disease in humans. |
Details | |||
|
-
|
-
|
V Viruses: Member States are to ensure that all viruses which have already been isolated in humains and which have not been assessed and allocated in this Annex are classified in group 2 as a minimum, except where Member States have proof that they are unlikely to cause disease in humans. |
Details | |||
|
-
|
-
|
V Viruses: Member States are to ensure that all viruses which have already been isolated in humains and which have not been assessed and allocated in this Annex are classified in group 2 as a minimum, except where Member States have proof that they are unlikely to cause disease in humans. |
Details | |||
|
-
|
-
|
V Viruses: Member States are to ensure that all viruses which have already been isolated in humains and which have not been assessed and allocated in this Annex are classified in group 2 as a minimum, except where Member States have proof that they are unlikely to cause disease in humans. |
Details | |||
|
-
|
-
|
V Viruses: Member States are to ensure that all viruses which have already been isolated in humains and which have not been assessed and allocated in this Annex are classified in group 2 as a minimum, except where Member States have proof that they are unlikely to cause disease in humans. |
Details | |||
|
-
|
-
|
V Viruses: Member States are to ensure that all viruses which have already been isolated in humains and which have not been assessed and allocated in this Annex are classified in group 2 as a minimum, except where Member States have proof that they are unlikely to cause disease in humans. |
Details | |||
|
200-962-3
|
76-44-8
|
Carc. 2; Acute Tox. 3; STOT RE 2 |
Details | |||
|
213-831-0
|
1024-57-3
|
Carc. 2; Acute Tox. 3; STOT RE 2 |
Details | |||
|
206-803-4
|
376-06-7
|
VPVB very Persistent and very Bioaccumulative (article 57e) |
Details | |||
|
203-767-1
|
110-43-0
|
Flam. Liq. 3; Acute Tox. 4 |
Details | |||
|
203-388-1
|
106-35-4
|
Flam. Liq. 3; Acute Tox. 4; Eye Irrit. 2 |
Details | |||
|
204-608-9
|
123-19-3
|
Flam. Liq. 3; Acute Tox. 4 |
Details | |||
|
205-563-8
|
142-82-5
|
Flam. Liq. 2; Asp. Tox. 1; Skin Irrit. 2; STOT SE 3 |
Details | |||
|
203-838-7
|
111-14-8
|
Skin Corr. 1B |
Details | |||
|
245-737-0
|
23560-59-0
|
Acute Tox. 3 |
Details | |||
|
-
|
-
|
V Viruses: Member States are to ensure that all viruses which have already been isolated in humains and which have not been assessed and allocated in this Annex are classified in group 2 as a minimum, except where Member States have proof that they are unlikely to cause disease in humans. |
Details | |||
|
-
|
-
|
V Viruses: Member States are to ensure that all viruses which have already been isolated in humains and which have not been assessed and allocated in this Annex are classified in group 2 as a minimum, except where Member States have proof that they are unlikely to cause disease in humans. |
Details | |||
|
-
|
-
|
V Viruses: Member States are to ensure that all viruses which have already been isolated in humains and which have not been assessed and allocated in this Annex are classified in group 2 as a minimum, except where Member States have proof that they are unlikely to cause disease in humans. |
Details | |||
|
show/hide
|
247-148-4
|
25637-99-4
|
Repr. 2; Lact. |
PBT Persistent, Bioaccumulative and Toxic (article 57d) |
Details | |
|
204-129-5
|
116-16-5
|
Acute Tox. 4 |
Details | |||
|
204-273-9
|
118-74-1
|
Carc. 1B; STOT RE 1 |
Details | |||
|
201-029-3
|
77-47-4
|
Acute Tox. 2; Acute Tox. 3; Acute Tox. 4; Skin Corr. 1B |
Details | |||